{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,1,17]],"date-time":"2024-01-17T00:35:50Z","timestamp":1705451750065},"reference-count":4,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,12,21]],"date-time":"2023-12-21T00:00:00Z","timestamp":1703116800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,12,21]],"date-time":"2023-12-21T00:00:00Z","timestamp":1703116800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Urologie"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1007\/s00120-023-02252-9","type":"journal-article","created":{"date-parts":[[2023,12,21]],"date-time":"2023-12-21T14:02:16Z","timestamp":1703167336000},"page":"100-101","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Gesamt\u00fcberleben und krebsspezifische Mortalit\u00e4t bei Patienten mit \u201every high-risk\u201c nicht-muskelinvasivem Urothelkarzinom der Harnblase (NMIBC)","Overall survival and cancer-specific mortality in patients with very high-risk non-muscle-invasive bladder cancer (NMIBC)"],"prefix":"10.1007","volume":"63","author":[{"given":"Henning","family":"Bahlburg","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florian","family":"Roghmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,12,21]]},"reference":[{"key":"2252_CR1","doi-asserted-by":"crossref","unstructured":"Kamat AM, Sylvester RJ, B\u00f6hle A, Palou J, Lamm DL, Brausi M et\u00a0al (2016) Definitions, end points, and clinical trial designs for non-muscle-invasive bladder cancer: recommendations from the international bladder cancer group. J\u00a0Clin Oncol 34:","DOI":"10.1200\/JCO.2015.64.4070"},{"key":"2252_CR2","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.eururo.2020.12.033","volume":"79","author":"RJ Sylvester","year":"2021","unstructured":"Sylvester\u00a0RJ, Rodr\u00edguez\u00a0O, Hern\u00e1ndez\u00a0V, Turturica\u00a0D, Bauerov\u00e1\u00a0L, Bruins\u00a0HM et\u00a0al (2021) European Association of Urology (EAU) Prognostic Factor Risk Groups for Non\u2013muscle-invasive Bladder Cancer (NMIBC) Incorporating the WHO 2004\/2016 and WHO 1973 Classification Systems for Grade: An Update from the EAU NMIBC Guidelines Panel[Formula presented. Eur Urol 79:4","journal-title":"Eur Urol"},{"key":"2252_CR3","doi-asserted-by":"crossref","unstructured":"Panebianco V, Narumi Y, Altun E, Bochner BH, Efstathiou JA, Hafeez S et\u00a0al (2018) Multiparametric magnetic resonance imaging for bladder cancer: development of VI-RADS (vesical imaging-reporting and data system). Eur Urol 74:","DOI":"10.1016\/j.eururo.2018.04.029"},{"key":"2252_CR4","doi-asserted-by":"crossref","unstructured":"Babjuk M, Burger M, Capoun O, Cohen D, Comp\u00e9rat EM, Dominguez Escrig JL et\u00a0al (2022) European association of urology guidelines on non\u2013muscle-invasive bladder cancer (Ta, T1, and carcinoma in situ). Eur Urol 81:","DOI":"10.1016\/j.eururo.2021.08.010"}],"container-title":["Die Urologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-023-02252-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00120-023-02252-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-023-02252-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,16]],"date-time":"2024-01-16T12:02:50Z","timestamp":1705406570000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00120-023-02252-9"}},"subtitle":["Retrospektive Analyse einer US-amerikanischen single-center Kohorte","Retrospective analysis of a US American single-center cohort"],"short-title":[],"issued":{"date-parts":[[2023,12,21]]},"references-count":4,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["2252"],"URL":"https:\/\/doi.org\/10.1007\/s00120-023-02252-9","relation":{},"ISSN":["2731-7064","2731-7072"],"issn-type":[{"value":"2731-7064","type":"print"},{"value":"2731-7072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,21]]},"assertion":[{"value":"23 November 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 December 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"H.\u00a0Bahlburg gibt an, dass kein Interessenkonflikt besteht. F.\u00a0Roghmann: Beratungst\u00e4tigkeit f\u00fcr Janssen, MSD, BMS, AstraZeneca, Astellas und Merck.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}